The opportunistic bulls are finding plenty of profitable action.
Leading advisors pick four favorite cannabis purveyors, two marijuana ETFs and one ancillary tobacco segment firm.
New technology could take out some of the pain -- and subjectivity -- for those looking to invest in this emerging line of treatments.
If you have a trader's mentality, there's a setup here worth watching.
Question: Would you rather buy the beer or the stock?
AdvisorShares Psychedelics ETF, which is adding Mindset Pharma and lists Cybin as a top holding, looks like a good trip.
I'm looking for a continuation of strong pockets of speculative action.
To help readers navigate this mushrooming opportunity, I've put together a list of the top corporate leaders in the field.
GRVI caters to multiple market segments like Beauty, Pet Care, Botanical Health & Wellness, Rare Cannabinoids, and even trade shows.
ETF MSOS is seen as an opportunity to get exposure to stocks that are not yet U.S. listed.